Detail akcie Lonza Group online

Business Summary: Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Financial Summary: BRIEF: For the six months ended 30 June 2024, Lonza Group AG revenues decreased 1% to SF3.06B. Net income decreased 20% to SF329M. Revenues reflect Capsules and Health Ingredients segment decrease of 9% to SF540M, Eliminations segment decrease of 39% to SF75M. Net income also reflects Net interest expenses on debt and bonds increase of 56% to SF53M (expense), Other operating income and expenses increase of 92% to SF25M (expense).